Skip to content

EBIT at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.11M+30.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$34.2M+59.2%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.17M-23.8%
Incyte logo
IncyteINCY
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Operating income-$42.0M-31.9%
Net income-$39.3M-39.6%
EPS (diluted)-$0.64-36.2%

Balance sheet

See full
Cash & equivalents$85.0M-15.7%
Total debt$5.7M-6.9%
Total equity$387.6M+19.8%
Total assets$412.0M+20.0%

Cash flow

See full
Operating cash flow-$32.6M-27.9%
CapEx$88.0K+529%
Free cash flow-$32.7M-28.2%

Valuation

See full
Market cap$1.81B+318%
Enterprise value$1.73B+397%

Returns & leverage

See full
Return on equity-36.9%+21.1pp
Debt / equity0.0×
Current ratio20.5×-2.3×

Where this comes from

Calculated from Tyra Biosciences, Inc.’s reported figures.

The official record: Tyra Biosciences, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tyra Biosciences, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tyra Biosciences, Inc.'s EBIT?
Tyra Biosciences, Inc. (TYRA) reported EBIT of -$42M in Q1 2026.
How has Tyra Biosciences, Inc.'s EBIT changed year-over-year?
Tyra Biosciences, Inc.'s EBIT decreased by 31.9% year-over-year, from -$31.85M to -$42M.
What is the long-term trend for Tyra Biosciences, Inc.'s EBIT?
Over 4 years (2021 to 2025), Tyra Biosciences, Inc.'s EBIT has grown at a 49.9% compound annual growth rate (CAGR), from -$26.29M to -$132.76M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.